Respiratory virus infection triggers acute psoriasis flares across different clinical subtypes and genetic backgrounds

diseases according to the Global Burden of Disease (GBD) and the current portfolio of CS reviews. 5 Diseases were grouped as to whether or not they were in the 'top 15', and whether or not previous work had identified a low representation within the CS portfolio. The final list of grouped titles was then reviewed by the CS clinical editors with respect to current titles and potential number of reviews that could be supported. The rankings were combined to generate an overall priority list. New titles were advertised for competitive application from suitably qualified and resourced author teams; priority titles currently in progress were supported with extra editorial resources. If an author team did not make adequate progress, extra support was offered from CS, or titles were readvertised for review by a new qualified and resourced team. For these priority titles, CS aims to produce high-quality systematic reviews within 18 months of title registration. Going forward, CS will continue to support our existing portfolio of reviews and protocols and consider author suggestions for new review titles on an annual basis in relation to editorial capacity at CS and ranking of related titles in the most recent prioritization exercise. Potential disadvantages include limited GBD data in some global regions that may skew title priority. CS will have an increasing focus on supporting high-priority, potentially high-impact systematic review titles generated by a formal prioritization process. This is consistent with the Cochrane Collaboration Strategy 2020, which aims to produce timely, high-priority reviews of evidence to guide health decision-making. 6 CS will repeat the 2017 prioritization process every 2-3 years to ensure our portfolio continues to include important and timely systematic review titles.